Stock Price Quote

PCI CHEMICALS & PHARMACEUTICALS LTD.

NSE : NABSE : 524792ISIN CODE : Industry : Pharmaceuticals & DrugsHouse : Private
BSE0.000 (0 %)
PREV CLOSE ( ) NA
OPEN PRICE ( ) 0.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )0.00 0.00
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1978
Management Info
- Chairman - Managing Director
Registered Office

Address 125, Arun Chambers, P M M Malviya Road Tardeo,
Mumbai,
Maharashtra-400034

Phone

Email --

Website NA

Registrars Details
PCI Chemicals & Pharmaceuticals Ltd.
125, Arun Chambers, P M M Malviya Road Tardeo,Mumbai
Listing : BSE

NEWS

No News Found

Financials

in Millions
QTR ANNUAL
Net Profit
Gross Profit
Operating Profit
Net Sales

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Hester Biosciences (BSE)
peergroup  2498.60 (20.00%)
M.Cap ( in Cr)2125.53
Procter&Gamble Healt (BSE)
peergroup  5061.65 (1.33%)
M.Cap ( in Cr)8402.03
Dr. Reddy's Lab (BSE)
peergroup  6008.70 (0.76%)
M.Cap ( in Cr)100242.96
Natco Pharma (BSE)
peergroup  1201.10 (2.30%)
M.Cap ( in Cr)21512.89
Alembic Pharma (BSE)
peergroup  868.60 (2.77%)
M.Cap ( in Cr)17073.47

Shareholding Pattern

No Data Found

About

no data found

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.